Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio announces $65 million Series B financing co-led by Aisling Capital and HBM Healthcare Investments to advance DR-01 and expand Platform

Click to view original post